ReviewFrontiers in cellular neuroscience2022
Cognitive impairment in psychiatric diseases: Biomarkers of diagnosis, treatment, and prevention.
Review in Frontiers in cellular neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Cognitive signs and symptoms in people with a psychiatric diagnosis on semaglutide: a retrospective cohort study of 13 007 patients in the USA.BMJ mental health · 2026Article
- Shared genetic and molecular architecture between insulin resistance and cognitive performance.medRxiv : the preprint server for health sciences · 2026Article
- Active Ingredients in Digital Cognitive Interventions: Integrating Dismantling Designs With Mechanistic Neuroscience.JMIR mental health · 2026Article
- Clinical Outcomes and Mortality Following Delirium: A Five-Year Follow-Up Study on Hospitalized Patients.Journal of clinical medicine · 2026Article
- Polygenic scores for executive functioning as predictors of performance improvements after repeated testing in major psychiatric disorders.Scientific reports · 2026Article
- Article
- MicroRNAs as biomarkers and molecular mediators of cognitive dysfunction in schizophrenia.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Schizophrenia Pathophysiology: Neurotransmitter Dysfunctions and Biomarker Frontiers.Current topics in medicinal chemistry · 2026Review
- APOE4 and doxorubicin impair inhibitory interneuron function and homeostatic regulation in the entorhinal cortex.PloS one · 2026Article
- Beyond Somatic Multimorbidity: Longitudinal Effects of Edentulism and Mental Health on Cognition in Older Adults.Journal of the American Medical Directors Association · 2025Article
- Unveiling the Interplay of EBV, HSV-1, and Inflammatory Biomarkers in Psychiatric Disorders.Journal of clinical medicine · 2025Article
- Assessing the Impact of Simplified Language on a Patient-Facing Pharmacogenetic Report: A User Comprehension Study.Journal of personalized medicine · 2025Article
- Exon-variant interplay and multi-modal evidence identify endocrine dysregulation in severe psychiatric disorders impacting excitatory neurons.Translational psychiatry · 2025Article
- Functional Remediation Improves Serum BDNF and TrkB Levels in Euthymic Patients with Bipolar Disorder: A Randomized Trial Study.Neuropsychiatric disease and treatment · 2025Article
- Clinical practice guidelines - An overview of cognitive remediation for various neuropsychiatric disorders.Indian journal of psychiatry · 2025Article
- The association between adult-life smoking and age-related cognitive decline in Danish men.PloS one · 2025Article
- Exploring the Morphological Study of the Brain in Patients with Bipolar Disorder Based on Structural Magnetic Resonance Imaging.Neuropsychiatric disease and treatment · 2025Article
- Role and Diagnostic Significance of Apolipoprotein D in Selected Neurodegenerative Disorders.Diagnostics (Basel, Switzerland) · 2024Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychiatric diseases, such as schizophrenia, bipolar disorder, autism spectrum disorder, and major depressive disorder, place a huge health burden on society. Cognitive impairment is one of the core characteristics of psychiatric disorders and a vital determinant of social function and disease recurrence in patients. This review thus aims to explore the underlying molecular mechanisms of cognitive impairment in major psychiatric disorders and identify valuable biomarkers for diagnosis, treatment and prevention of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.